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Abstract: The treatment of moderate or severe hypertension in most cases requires the 
contemporaneous use of multiple antihypertensive agents. The most available two-drug 
combinations have an agent that addresses renin secretion and another one that is statistically 
more effective in renin-independent hypertension. The practice of combining agents that 
counteract different mechanisms is the most likely explanation for the fact that most available 
two-drug combinations have an agent that addresses renin secretion (beta-blocker, angiotensin 
converting enzyme inhibitor, angiotensin II receptor blocker or direct renin inhibitor) and 
another one that is more effective in renin-independent hypertension (diuretic, dihydropyridine 
or non-dihydropyridine calcium channel blocker). Based on these considerations, addition of 
hydrochlorothiazide to the combination of an antagonist of the renin-angiotensin system with a 
calcium channel blocker would constitute a logical approach. Inclusion of a diuretic in the triple 
combination is based on the evidence that these agents are effective and cheap, enhance the effect 
of other antihypertensive agents, and add a specific effect to individuals with salt-sensitivity 
of blood pressure. The benefit of triple combination therapy with amlodipine, valsartan and 
hydrochlorothiazide over its dual component therapies has been demonstrated, and the use of 
a single pill will simplify therapy resulting in better blood pressure control.
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Introduction
Although a common and treatable risk factor for cardiovascular morbidity and mor-
tality, hypertension (blood pressure  140/90 mmHg) is highly prevalent, affecting 
approximately one billion individuals worldwide.1,2 Concomitant with our progres-
sive understanding of the epidemiology of hypertension and the beneficial effects of 
  treatment, there has been a progressive lowering of the blood pressure values considered 
as the optimal treatment target. Even though awareness and treatment of hypertension 
have increased over the years, substantial improvements in blood pressure control rates 
are still lacking, with about two thirds of hypertensive adults aged 35–64 years failing 
to reach a blood pressure target of 140/90 mmHg,3 thus contributing to the negative 
result stating that the total control rates remain low, varying from 5% to 33%.3–5 Nowa-
days, it is postulated that hypertension must be considered a multifactorial disease, 
often requiring multiple drugs for its management, and the majority of hypertensive 
patients require two or more agents to reach a blood pressure goal. Particularly for those 
patients with stage 2 hypertension (or blood pressure  20/10 mmHg above goal), it 
is recommended that treatment begins with a combination of two drugs from differ-
ent classes.2,5,6 And, for patients who do not respond to dual therapy, the addition of a Vascular Health and Risk Management 2010:6 254
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third drug is usually necessary. As a matter of fact, although 
numerous single-pill combinations with two drugs are already 
available, blood pressure remains largely uncontrolled, more 
so in elderly, black, diabetic, obese, and severely hypertensive 
patients.7–9 Data from different countries show that up to 85% 
of patients may need multiple medications to help control 
their blood pressure,10 and many need three or more.11
Combining drugs with complimentary modes of action is 
pragmatic, as it is more likely to achieve better blood pres-
sure control, and also attenuate the adverse events (AEs) 
of the constituent monotherapy.12–14 Furthermore, the risk 
of non-compliance, one of the major reasons for failure of 
antihypertensive therapy, is reduced by 24% to 26% with 
the use of single-pill combination regimens. The absence of 
proper blood pressure control in the population is not only 
due to the patients’ non-compliance and/or non-adherence to 
treatment, but also a part of responsibility can be attributed 
to the physicians; none excluded!
From our point of view, the two most powerful elements 
with which physicians can increase blood pressure control 
rates are self-management of therapeutic inertia and appro-
priate selection of drug therapy. Therapeutic inertia can be 
defined as the failure to initiate or increase therapy when indi-
cated, despite clearly-established guidelines and documented 
beneficial outcomes.15,16 This behavior is independent from 
patient issues with adherence or access to care, and most 
probably results from relying on “poor and weak” reasons for 
not modifying therapy, or a lack of organization. Productivity 
pressures that shorten the patient-physician interaction, and 
the multiple, sometimes conflicting, guidelines regarding 
therapy compound the issue. However, it has been argued 
that correcting inertia may not be enough to obtain blood 
pressure control in all the types of patients. A recent and 
interesting study employing a modification of survival17 
demonstrated the diminished efficacy of antihypertensive 
therapy in the elderly. If therapeutic inertia by physicians is 
also increased, it would result in blood pressure control rates 
under 65%, even if the elderly were treated as aggressively 
as the youngest studied group.
Not only epidemiological or observational studies but 
also important and wide clinical trials, including ALLHAT 
(Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial), ACCOMPLISH (Avoiding Cardiovascu-
lar Events in Combination Therapy in Patients Living with 
Systolic Hypertension), INVEST (International Verapamil 
SR/Trandolapril Study), and LIFE (Losartan Intervention 
For Endpoint reduction in Hypertension), have reported that 
23% to 54% of patients require three or more antihypertensive 
agents for blood pressure control and target level maintenance 
(140/90 or 130/80 mmHg depending on cardiovascular 
risk).18–21 In patients with blood pressure  20/10 mmHg above 
goal, on average, 3.2 drugs might be needed to achieve blood 
pressure control.22 Thus, a single-pill combination of three 
drugs would be a desired treatment option for hypertension, 
and also because it is supposed to reduce the side effects of 
any single molecule.
Rationale for fixed combinations
Rather than a protracted vicious circle of ever-increasing 
monotherapy dosages, with the potential for more adverse 
events, the rapid achievement of blood pressure goals has 
the obvious advantage of reducing patient frustration. This 
therefore increases trust in the therapeutic relationship and, 
hence, adherence to treatment.23
Furthermore, regardless of the specific question posed in 
a particular clinical trial, studies exploring hypertension treat-
ment outcomes have attempted to reach increasingly tighter 
blood pressure control levels. Coupled with the reduction of 
side effects, this leads to a significant increase in therapeutic 
compliance. Thus, the need for more drugs to achieve blood 
pressure control, the issues of convenience, and side effects 
affecting adherence led to the development of single-pill 
combination therapies involving almost all the newest classes 
of antihypertensive agents. The practice of combining agents 
that counteract different mechanisms is likely to be the reason 
why most available two-drug combinations have an agent that 
addresses renin secretion (beta-blocker, ACE-I [angiotensin 
converting enzyme inhibitor], ARB [angiotensin II receptor 
blocker] or DRI [direct renin inhibitor]) and another one that 
is more effective in renin-independent hypertension (diuretic, 
dihydropyridine, or non-dihydropyridine calcium channel 
blocker [CCB]). For these reasons, addition of hydrochloro-
thiazide (HCTZ) to the combination of an antagonist of the 
renin-angiotensin system (ACE inhibitor, ARB, or DRI) and 
a CCB would constitute a logical approach. Inclusion of a 
diuretic in the triple combination is based on the evidence 
that these agents are effective and cheap, enhance the effect 
of other antihypertensive agents, and add a specific effect for 
individuals with salt-sensitivity of blood pressure. This last 
mechanism is not yet fully understood, but there is strong 
evidence that deficient natriuretic derivatives of cytochrome 
p450 metabolism of arachidonic acid play an important role 
both in rodents24 and humans.25,26
The best known triple fixed combination available 
nowadays is the one which combines the CCB amlodipine, 
the ARB valsartan, and the diuretic HCTZ. Specifically, Vascular Health and Risk Management 2010:6 255
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amlodipine blocks the contractile effects of calcium on 
cardiac and vascular smooth muscle cells; valsartan blocks the 
vasoconstriction and sodium retaining effects of angiotensin II 
on cardiac and vascular smooth muscle, adrenal and renal 
cells; and, finally, hydrochlorothiazide promotes the excretion 
of sodium and chloride in the kidney, leading to reductions in 
intravascular volume. A brief description of the mechanism 
of action of each individual component follows.
Amlodipine
Amlodipine is a peripheral arterial vasodilator that acts 
directly on vascular smooth muscle to cause a reduction in 
peripheral vascular resistance and reduction in blood pres-
sure. It is a dihydropyridine CCB that inhibits the transmem-
brane influx of calcium ions into vascular smooth muscle 
and cardiac muscle. The contractile processes of cardiac 
muscle and vascular smooth muscle are dependent upon 
the movement of extracellular calcium ions into these cells 
through specific ion channels. Amlodipine inhibits calcium 
ion influx across cell membranes selectively, with a greater 
effect on vascular smooth muscle cells than on cardiac 
muscle cells. Due to these mechanisms of action, amlodipine 
produces mostly arterial vasodilatation. Since the CCB does 
not promote a venous dilatation comparable to the arterial 
effect, a displacement of hydrostatic forces in peripheral 
capillaries is created which facilitates fluid extravasation into 
the interstitial space. This often results in lower extremities 
edema due to the force of gravity. However, when associated 
with valsartan, the presence of an ARB promotes both arterial 
and venous dilation, so balancing the hydrostatic pressure in 
peripheral capillaries and thus reducing fluid extravasation 
into the interstices. The end result is a difference in lower 
extremity edema (Figure 1).
With chronic once-daily administration, antihypertensive 
effectiveness is maintained for at least 24 hours. Plasma con-
centrations correlate with effect in both young and elderly 
patients. The magnitude of reduction in blood pressure with 
amlodipine is also correlated with the pre-treatment blood 
pressure. Thus, individuals with moderate hypertension 
(diastolic pressure 105–114 mmHg) have about 50% greater 
response than patients with mild hypertension (diastolic pres-
sure 90–104 mmHg). In hypertensive patients with normal 
renal function, therapeutic doses of amlodipine result in 
a decrease in renal vascular resistance and an increase in 
intraglomerular filtration rate and effective renal plasma flow 
without change in filtration fraction or proteinuria.
• Arteriodilation
• RAS blockade
• CHF and renal
   benefits
• RAS activation
• No renal or CHF
   benefits
• Peripheral edema
• Effective in low-renin patients
• Effective in high-renin
   patients
• Reduces cardiac ischemia
• No effect on cardiac
   ischemia
• Venodilation
• Attenuates peripheral edema
Synergistic
BP
reduction
complementary
clinical benefits
CCB
CCB
ARB
ARB
BP
Figure 1 CCB–ARB: synergy of counter-regulation. 
Abbreviations: ARB, angiotensin receptor blocker; BP, blood presssure; CCB, calcium channel blocker; CHF, congestive heart failure; RAS, renin-angiotensin system. Vascular Health and Risk Management 2010:6 256
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Valsartan
Valsartan’s action is to block the vasoconstrictor and 
aldosterone-secreting effects of angiotensin II. This is 
acheived by selectively blocking the binding of angiotensin 
II to the angiotensin II type 1 (AT1) receptor in many tissues, 
such as vascular smooth muscle and the adrenal gland. Thus, 
its action is independent of the pathways for angiotensin II 
  synthesis. There is also an angiotensin II type 2 (AT2) recep-
tor found in many tissues. But AT2 is not known to be linked 
with cardiovascular homeostasis. Valsartan has much greater 
affinity (about 20,000-fold) for the AT1 receptor than for the 
AT2 receptor. The increased plasma levels of angiotensin fol-
lowing AT1 receptor blockade with valsartan could produce 
a stimulation of the unblocked AT2 receptors (Figure 2). 
Because valsartan does not inhibit ACE (kininase II), it does 
not affect the response to bradykinin, as happens with the 
use of ACE inhibitors. It is well-known that the blockade of 
the angiotensin II receptor inhibits the negative regulatory 
feedback of angiotensin II on renin secretion. However, the 
resulting increased plasma renin activity and angiotensin II 
circulating levels do not overcome the effect of valsartan on 
blood pressure.
In multiple-dose studies of hypertensive patients with 
stable renal insufficiency and patients with renovascular 
hypertension, valsartan had no clinically significant effects 
on glomerular filtration rate, filtration fraction, creatinine 
clearance, or renal plasma flow. Administration of valsartan 
to patients with essential hypertension results in a significant 
reduction of sitting, supine, and standing systolic blood 
  pressure, usually with little or no orthostatic change.
Hydrochlorothiazide
HCTZ is a thiazide diuretic. Thiazides affect the renal tubular 
mechanisms of electrolyte resorption, directly increasing 
excretion of the ions sodium and chloride in approximately 
equivalent amounts. After oral administration of HCTZ, 
diuresis begins within 2 hours, peaks in about 4 hours, and 
lasts about 6 to 12 hours. Indirectly, the diuretic action of 
HCTZ reduces plasma volume, with consequent increases 
of plasma renin activity, aldosterone secretion, urinary loss, 
and decreases of serum potassium. The renin-aldosterone 
link is mediated by angiotensin II, so co-administration of 
an angiotensin II receptor-antagonist tends to equilibrate the 
potassium loss associated with these diuretics.
Pharmacokinetics
Following oral administration of the single-pill triple combi-
nation in normal healthy adults, peak plasma concentrations 
of amlodipine, valsartan and HCTZ are reached in about 
6 hours, 3 hours, and 2 hours, respectively. The rates and 
extents of absorption of amlodipine, valsartan and HCTZ 
from the single-pill triple combination are the same as when 
administered as individual dosage forms, as confirmed by the 
results of a dedicated study.27 Peak plasma concentrations of 
Angiotensinogen
Angiotensin I
Angiotensin-converting enzyme
Angiotensin II
Non-ACE
(e.g. chymase)
Vasoconstriction
cell growth
sodium/water retention
sympathetic activation
Valsartan
Vasodilation
antiproliferation
Sodium/water
Aldosterone
AT1 receptor
AT2 receptor
Figure 2 Mechanism of action of valsartan.
Abbreviations: ACE, angiotensin converting enzyme; AT1, angiotensin II type 1; AT2, angiotensin II type 2.Vascular Health and Risk Management 2010:6 257
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amlodipine are reached 6–12 hours after administration of 
amlodipine alone. Absolute bioavailability has been estimated 
to be between 64% and 90%. Following oral administration 
of valsartan alone, peak plasma concentrations of valsartan 
are reached in 2 to 4 hours. Absolute bioavailability is about 
25% (range 10%–35%). The pharmacokinetics of valsartan 
do not differ significantly between males and females. HCTZ 
is not metabolized but is eliminated rapidly by the kidney. 
At least 61% of the oral dose is eliminated as unchanged 
drug within 24 hours. The elimination half-life is between 
5.8 and 18.9 hours.
Overview of recent clinical studies
Most of the studies testing the triple combination of 
amlodipine/valsartan/HCTZ compare it to the double 
combination of valsartan/amlodipine or valsartan/HCTZ or 
amlodipine/HCTZ. In a recent study, our group showed that, 
in patients with stage 2 hypertension receiving HCTZ add-on 
if blood pressure  130 mmHg, treatment with amlodip-
ine/valsartan, with or without HCTZ, was more efficacious 
than treatment with amlodipine with or without HCTZ28 
(Figure 3). The addition of HCTZ in this design followed the 
general clinical practice of adding another agent only if the 
patients are unable to achieve a target blood pressure level.
Another quite recent and interesting randomized forced-
titration study has demonstrated that patients with moderate-
to-severe hypertension receiving a triple combination of 
amlodipine, valsartan and HCTZ had significantly greater 
blood pressure reductions and control rates compared to 
patients receiving the dual component therapies.29 Again, 
Deeks recently published the results of a large, 8-week, 
randomized, double-blind, multinational, phase III trial.30 
The author demonstrated that in patients with moderate 
or severe hypertension, triple combination therapy with 
amlodipine/valsartan/HCTZ produces significantly greater 
reductions from baseline in mean sitting systolic blood 
pressure (msSBP) and mean sitting diastolic blood pressure 
(msDBP) than either valsartan/HCTZ, amlodipine/HCTZ, 
or amlodipine/valsartan. Furthermore, the proportion of 
patients achieving overall blood pressure control at endpoint 
was significantly greater with the triple combination regimen 
than with any of the dual regimens, with significantly more 
triple combination recipients achieving msSBP and msDBP 
control at each assessment throughout the trial, independent 
of age, race, gender and ethnicity.30
The study CVEA489A230231 played a very important 
role in obtaining the European Commission’s approval of the 
new 3-in-1 once-daily hypertension treatment. It is a multi-
national, randomized, double-blind, parallel-group, phase III 
study designed to compare the efficacy and safety of triple 
therapy (valsartan, amlodipine and HCTZ) with the various 
dual combinations of its components, such as valsartan/HCTZ, 
amlodipine/valsartan, or amlodipine/HCTZ, in patients with 
moderate-to-severe hypertension. The trial was conducted 
in 15 countries, with 2,271 patients randomized to double-
blind treatment. Study CVEA489A2302 showed that triple 
therapy was more effective in reducing systolic and diastolic 
blood pressure than dual combinations of its components in 
patients with moderate-to-severe hypertension. Reductions 
in msSBP of 40 to 50 mmHg were achieved, with up to 58% 
Screening
Amlo/Val 5/160
WASH OUT
1 week Amlo 5 mg
Randomization 2 4
Amlodipine
Amlodipine/
10 mg
Valsartan 10/160 mg
+ HCTZ 12.5 mg
+ HCTZ 12.5 mg
8 wks
Figure 3 Efficacy of amlodipine/valsartan compared with amlodipine monotherapy in patients with grade 2 + 3 hypertension: Study design.28
Abbreviations: Amlo, amlodipine; Val, valsartan; HCTZ, hydrochlorothiazide; wks, weeks.Vascular Health and Risk Management 2010:6 258
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more patients receiving triple therapy achieving overall blood 
pressure control (defined as 140/90 mmHg) versus dual 
therapy. Of particular interest is the fact that the maximum dose 
of triple therapy (valsartan/amlodipine/HCTZ 10/320/25 mg) 
demonstrated additional reductions of 18%–29% in systolic 
blood pressure and 19%–32% in diastolic blood pressure 
when compared to all dual combinations of its components 
at the same doses. Furthermore, ambulatory blood pressure 
monitoring showed that the blood pressure-lowering effect of 
triple therapy was maintained throughout the 24-hour period. 
In addition, this study showed that triple therapy was highly 
effective regardless of the patient’s age, gender, race, ethnicity 
or baseline blood pressure, and was generally well-tolerated 
compared with dual therapy.31
Discussion
In a press release issued by Novartis,32 David A Calhoun, 
MD (University of Alabama at Birmingham), commented 
that “the majority of people with hypertension will require 
more than 1 medication to control their blood pressure, and 
it is not uncommon for patients with severe hypertension 
and/or patients requiring stricter blood pressure control to 
need 3 or more medications. With a triple combination option, 
appropriate patients may experience a simpler routine of a 
convenient, once-daily pill to help them control their high 
blood pressure.”
Furthermore, we can also say that combination therapy 
is increasingly recommended for selected patients with 
hypertension to facilitate prompt attainment and mainte-
nance of goal blood pressure. Clearly enough, the possibility 
of a single-pill combination therapy simplifies treatment 
and optimizes long-term compliance. Moreover, therapies 
combining drugs with complimentary mechanisms of 
action like amlodipine (a CCB), valsartan (an ARB) and 
HCTZ (a diuretic) have been shown to achieve better blood 
pressure control and attenuate AEs like peripheral edema 
and hyperkalemia.9,33,34 Also, it has been suggested that 
combining different drugs in a single pill may lead to better 
compliance and hence better blood pressure control.35,36 Most 
of the studies concerning combination therapy have shown 
that, although dual therapy with amlodipine/valsartan is still 
indicated as initial therapy in patients who are unlikely to be 
controlled with a single drug. and as second-line therapy in 
patients not responding adequately to monotherapy, triple 
combination therapy with amlodipine/valsartan/HCTZ 
has greater blood pressure-lowering efficacy and is well-
tolerated compared to the dual therapy with amlodipine/
HCTZ, and, in stage 2 hypertension, can provide additional 
benefits in patients who require more than 2 agents to reach 
their target blood pressure. In addition to covering major 
pathophysiological mechanisms and providing a treatment 
for resistant hypertension (currently defined as the failure to 
reach risk factor-tailored goal blood pressure, despite treat-
ment with optimal doses of three pharmacological agents 
of different families, one of which is a diuretic), the agents 
used in this type of combination have outcome data to sup-
port their use in diverse patient populations.37
Mostly following some of the evidence mentioned above, 
the first fixed-dose combination pill containing 3 drugs was 
approved for use in the United States by the Food and Drug 
Administration (FDA)38 in April 2009. In fact, it combines 
the CCB amlodipine, the ARB valsartan, and the diuretic 
HCTZ.39 This triple combination has been indicated for 
the treatment of hypertension, but not as an initial therapy. 
Tablets are available in fixed dosages of amlodipine/valsar-
tan/HCTZ of 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg, 
10/160/25 mg, and 10/320/25 mg. Dosing is once-daily. 
According to the FDA, a patient may be switched to the 
triple or the triple may be added if blood pressure is not 
adequately controlled with any 2 antihypertensive drugs 
from the classes of CCBs, ARBs, and diuretics. In con-
clusion, if we are to effectively deal with the worldwide 
cardiovascular epidemic, we believe that even with well-
chosen double and triple combinations, there will still be 
a substantial number of patients who will need additional 
antihypertensive therapy. Thus, we (the physicians) should 
never feel satisfied with our job just because we are using 
a new class or a new combination of molecules. Our aim 
must be to achieve an effective and rapid reduction of blood 
pressure, always adapting our beliefs to the effective results 
obtained with our patients.
Disclosures
Dr Destro reports receiving consulting and lecture fees 
from Novartis Pharma, Boehringer Ingelheim, AstraZeneca, 
Servier, Menarini IFR, Schering-Plough, Guidotti, Pfizer, 
Knoll, Bayer, Chiesi, Sankyo, Merck Sharp & Dohme, 
Malesci and Errekappa; he has received research support 
as a study investigator from Novartis Pharma, Boehringer 
Ingelheim, Menarini IFR, Guidotti, Bayer and Chiesi. 
Dr Preti reports receiving consulting and lecture fees and 
research support as a study investigator from Novartis 
Pharma. Dr Cagnoni and Dr Rossi Ricci report receiving 
research support as a study co-investigator from Novartis 
Pharma. No other potential conflict of interest relevant to 
this article was reported.Vascular Health and Risk Management 2010:6 259
Therapy with fixed combination of valsartan, amlodipine and hydrochlorothiazide Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
References
  1.  Kearney P, Whelton M, Reynolds K, Muntner P, Whelton P, He J. 
Global burden of hypertension: Analysis of worldwide data. Lancet. 
2005;365(9455):217–223.
  2.  Chobanian A, Bakris G, Black H. Seventh report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure. Hypertension. 2003;42:1206–1252.
  3.  Wolf-Maier K, Cooper R, Kramer H, et al. Hypertension treatment 
and control in five European countries, Canada, and the United States. 
Hypertension. 2004;43:10–17.
  4.  Antikainen R, Moltchanov V , Chukwuma C, et al. Trends in the preva-
lence, awareness, treatment and control of hypertension: The WHO 
MONICA Project. Eur J Cardiovasc Prev Rehabil. 2006;13:13–29.
  5.  Mancia G, De Backer G, Dominiczak A, et al; for ESH-ESC Task Force 
on the Management of Arterial Hypertension. 2007 ESH-ESC practice 
guidelines for the management of arterial hypertension. J Hypertens. 
2007;25(9):1751–1762.
  6.  Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European 
guidelines on hypertension management: A European Society of Hyper-
tension Task Force document. J Hypertension. 2009;27:923–934.
  7.  UK Prospective Diabetes Study Group. Tight blood pressure control 
and risk of macrovascular and microvascular complications in type 2 
diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713.
  8.  Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine 
GITS or co-amilozide in hypertensive diabetics and nondiabetics in 
Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 
2003;41(3):431–436.
  9.  Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined 
and as monotherapy in stage 2, elderly, and black hypertensive patients: 
Subgroup analyses of 2 randomized, placebo-controlled studies. J Clin 
Hypertens. 2007;9(5):355–364.
  10.  Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium 
antagonist vs a non-calcium antagonist hypertension treatment strategy 
for patients with coronary artery disease. The International Verapamil-
Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 
2003;290(21):2805–2816.
  11.  Grosso A, Jin J, Chen J. An 8-week, multi-centre, randomized, 
double-blind, parallel-group study to evaluate the efficacy and safety 
of the combination of valsartan/HCTZ/amlodipine compared to 
valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in 
patients with moderate to severe hypertension. Novartis Full Clinical 
Study Report. 2008.
  12.  Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular 
events with an antihypertensive regimen of amlodipine adding per-
indopril as required versus atenolol adding bendroflumethiazide as 
required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised 
controlled trial. Lancet. 2005;366(9489):895–906.
  13.  Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese 
population with hypertension and other cardiovascular disease (Jikei 
Heart Study): A randomised, open-label, blinded endpoint morbidity-
mortality study. Lancet. 2007;369:1431–1439.
  14.  Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood 
pressure-lowering efficacy of the combination of amlodipine plus 
valsartan compared with lisinopril plus hydrochlorothiazide in adult 
patients with stage 2 hypertension. Clin Ther. 2007;29(2):279–289.
  15.  Elliott WJ. What factors contribute to the inadequate control of elevated 
blood pressure? J Clin Hypertens. 2008;10(1 Suppl 1):20–26.
  16.  Phillips L, Branch W, Cook C, et al. Clinical inertia. Ann Intern Med. 
2001;135:825–834.
  17.  Bailey K, Grossardt B, Graves J. Novel use of Kaplan-Meier methods 
to explain age and gender differences in hypertension control rates. 
Hypertension. 2008;51:841–847.
  18.  Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine 
or hydrochlorothiazide for hypertension in high-risk patients. N Engl 
J Med. 2008;359(23):2417–2428.
  19.  Devereux RB, de Faire U, Fyhrquist F, et al. Blood pressure reduction and 
antihypertensive medication use in the losartan intervention for endpoint 
reduction in hypertension (LIFE) study in patients with hypertension 
and left ventricular hypertrophy. Curr Med Res Opin. 2007;23(2):259–
270.
  20.  Bangalore S, Messerli FH, Cohen JD, et al. Verapamil-sustained 
release-based treatment strategy is equivalent to atenolol-based 
treatment strategy at reducing cardiovascular events in patients with prior 
myocardial infarction: An INternational VErapamil SR-Trandolapril 
(INVEST) substudy. Am Heart J. 2008;156(2):241–247.
  21.  Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of 
blood pressure control in diverse North American settings: the anti-
hypertensive and lipid-lowering treatment to prevent heart attack trial 
(ALLHAT). J Clin Hypertens. 2002;4(6):393–404.
  22.  Turnbull F. Effects of different blood-pressure-lowering regi-
mens on major cardiovascular events: Results of prospectively-
designed overviews of randomised trials. Lancet. 2003;362(9395): 
1527–1535.
  23.  Gradman A, Acevedo C. Evolving strategies for the use of combination 
therapy in hypertension. Curr Hypertens Rep. 2002;4:343–349.
  24.  Ma Y, Schwartzman M, Roman R. Altered renal P-450 metabolism of 
arachidonic acid in Dahl salt-sensitive rats. Am J Physiol. 1994;267:
R579–589.
  25.  Laffer C, Gainer J, Waterman M, et al. The T8590C polymorphism of 
CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hyperten-
sion. Hypertension. 2008;51:767–772.
  26.  Laffer C, Laniado-Schwartzman M, Wang M, Nasjletti A, Elijovich F. 
Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic acid 
in human salt-sensitive versus salt-resistant hypertension. Circulation. 
2003;107:574–578.
  27.  Novartis. CVEA489A2104: A multi-center, multiple dose, open-label, 
four-cohort, parallel study to assess the pharmacokinetic drug interac-
tion following co-administration of valsartan, hydrochlorothiazide 
and amlodipine in patients with hypertension. Novartis Clinical Trials 
Results Database. 2009. Available from: http://www.novctrd.com/
ctrdWebApp/clinicaltrialrepository/public/login.jsp.
  28.  Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and 
safety of amlodipine/valsartan compared with amlodipine monotherapy 
in patients with stage 2 hypertension: a randomized, double-blind, 
multicenter study: The EX-EFFeCTS Study. J Am Soc Hypertens. 
2008;2:294–302.
  29.  Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihyper-
tensive therapy with amlodipine, valsartan, and hydrochlorothiazide: 
A randomized clinical trial. Hypertension. 2009;54:32–39.
  30.  Deeks E. Amlodipine/valsartan/hydrochlorothiazide: Fixed-dose 
  combination in hypertension. Am J Cardiovasc Drugs. 2009;9:411–418.
  31.  Novartis. CVEA489A2302: An 8-week, multicenter, randomized, 
double-blind, parallel-group study to evaluate the efficacy and safety of 
the combination of valsartan/HCTZ/amlodipine compared to valsartan/
HCTZ, valsartan/amlodipine, and HCTZ/amlodipine inpatients with 
moderate to severe hypertendion. Novartis Clinical Trials Results 
Database. 2009. Available from: http://www.novctrd.com/ctrdWebApp/
clinicaltrialrepository/public/login.jsp.
  32.  Novartis. FDA approves Exforge HCT® – the only high blood pres-
sure treatment to combine three medications in a single pill. 2009. 
Available from: http://www.novartis.com/newsroom/media-releases/
en/2009/1310474.shtml. Accessed June 3, 2009.
  33.  Schrader J, Salvetti A, Calvo C, et al. The combination of amlodipine/
valsartan 5/160 mg produces less peripheral oedema than amlodip-
ine 10 mg in hypertensive patients not adequately controlled with 
amlodipine 5 mg. Int J Clin Pract. Feb 2009;63(2):217–225.
  34.  Kjeldsen SE AT, Sierra ADL, et al. Amlodipine and valsartan: calcium 
channel blockers/angiotensin II receptor blockers combination for 
hypertension. Drug Eval. 2007;4:31–40.
  35.  Gerbino PP, Shoheiber O. Adherence patterns among patients treated 
with fixed-dose combination versus separate antihypertensive agents. 
Am J Health Syst Pharm. 2007;64(12):1279–1283.Vascular Health and Risk Management 2010:6
Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
260
Destro et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
  38.  Yusuf SW, Ali SS, Swafford J, et al. Culture-positive and culture-negative 
endocarditis in patients with cancer: A retrospective observational study, 
1994–2004. Medicine. 2006;85(2):86–94.
  39.  Novartis Pharmaceuticals Corporation (East Hanover NJ). Exforge 
HCT®: Highlights of prescribing information. 2009. Available from: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022314lbl.
pdf. Accessed April 30, 2009.
  36.  Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relation-
ship of blood pressure control to adherence with antihypertensive 
monotherapy in 13 managed care organizations. J Manag Care Pharm. 
2006;12(3):239–245.
  37.  Destro M, Crikelair N, Yen J, Glazer R. Triple therapy with amlodipine, 
valsartan, and HCTZ in Stage 2 hypertensive patients. Curr Med Res 
Opin. In press.